{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:48:09Z","timestamp":1777337289751,"version":"3.51.4"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Generation of human hematopoietic stem and progenitor cells (HSPCs) from pluripotent stem cells (PSCs) holds significant promise in disease modeling, drug screening, and the development of cell and gene therapies for various hematologic and nonhematologic disorders. However, efficient and consistent derivation of functional HSPCs remains a major challenge hindering their practical use in biomedical research and applications. One of the contributing factors is the use of human serum albumin (HSA), which has been widely regarded as essential for supporting ex vivo maintenance, expansion, and differentiation of human stem cells and their derivatives. The lot-to-lot variation of this critical reagent can contribute to inconsistent laboratory results and high manufacturing costs. In this study, we address the manufacturing and regulatory challenges associated with using HSA in HSPC differentiation and propose an approach using a caprolactam-based polymer as an alternative. Our differentiation method demonstrates robust HSPC generation across various embryonic and induced PSC lines and culture conditions, highlighting its adaptability and reliability. Importantly, PSC-derived HSPCs exhibit functional versatility in differentiation capacity into myeloid and lymphoid lineages, as validated through colony-forming assays as well as directed red blood cell and NK cell differentiations. These findings suggest that HSA is dispensable in HSPC differentiation and replacing it with synthetic polymers has the potential to mitigate lot-to-lot reagent variation, improve HSPC production consistency, lower manufacturing costs, and expedite clinical applications.<\/jats:p>","DOI":"10.1093\/stcltm\/szag020","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:48:06Z","timestamp":1770900486000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficient and robust generation of functional hematopoietic cells from human pluripotent stem cells in albumin-free conditions"],"prefix":"10.1093","volume":"15","author":[{"given":"Byung Woo","family":"Kim","sequence":"first","affiliation":[{"name":"Gene Transfer and Immunogenicity Branch, Division of Gene Therapy 2, Office of Gene Therapy CMC, Office of Therapeutic Products, Center for Biologics Evaluation and Research, Food and Drug Administration , Silver Spring, MD 20993,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linyi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Gene Transfer and Immunogenicity Branch, Division of Gene Therapy 2, Office of Gene Therapy CMC, Office of Therapeutic Products, Center for Biologics Evaluation and Research, Food and Drug Administration , Silver Spring, MD 20993,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mo","family":"Liu","sequence":"additional","affiliation":[{"name":"Gene Transfer and Immunogenicity Branch, Division of Gene Therapy 2, Office of Gene Therapy CMC, Office of Therapeutic Products, Center for Biologics Evaluation and Research, Food and Drug Administration , Silver Spring, MD 20993,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Supreet","family":"Khanal","sequence":"additional","affiliation":[{"name":"Tumor Vaccine and Biotechnology Branch, Division of Cell Therapy 2, Office of Cellular Therapy and Human Tissue CMC, Office of Therapeutic Products, Center for Biologics Evaluation and Research, Food and Drug Administration , Silver Spring, MD 20993,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye Eun","family":"Jeong","sequence":"additional","affiliation":[{"name":"Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration , Silver Spring, MD 20993,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ge","family":"Zheng","sequence":"additional","affiliation":[{"name":"Gene Transfer and Immunogenicity Branch, Division of Gene Therapy 2, Office of Gene Therapy CMC, Office of Therapeutic Products, Center for Biologics Evaluation and Research, Food and Drug Administration , Silver Spring, MD 20993,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirjal","family":"Bhattarai","sequence":"additional","affiliation":[{"name":"Tumor Vaccine and Biotechnology Branch, Division of Cell Therapy 2, Office of Cellular Therapy and Human Tissue CMC, Office of Therapeutic Products, Center for Biologics Evaluation and Research, Food and Drug Administration , Silver Spring, MD 20993,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5272-9168","authenticated-orcid":false,"given":"Zhaohui","family":"Ye","sequence":"additional","affiliation":[{"name":"Gene Transfer and Immunogenicity Branch, Division of Gene Therapy 2, Office of Gene Therapy CMC, Office of Therapeutic Products, Center for Biologics Evaluation and Research, Food and Drug Administration , Silver Spring, MD 20993,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"2026042720031301000_szag020-B1","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.1182\/blood-2009-03-191304","article-title":"Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells","volume":"114","author":"Kaufman","year":"2009","journal-title":"Blood"},{"key":"2026042720031301000_szag020-B2","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/ncb3419","article-title":"Progress towards generation of human haematopoietic stem cells","volume":"18","author":"Wahlster","year":"2016","journal-title":"Nat Cell Biol"},{"key":"2026042720031301000_szag020-B3","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.4161\/cc.10.17.17180","article-title":"Hematopoietic cells as sources for patient-specific iPSCs and disease modeling","volume":"10","author":"Ye","year":"2011","journal-title":"Cell Cycle"},{"key":"2026042720031301000_szag020-B4","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/j.ajt.2023.05.020","article-title":"Induced pluripotent stem cell-derived hematopoietic stem and progenitor cells induce mixed chimerism and donor-specific allograft tolerance","volume":"23","author":"Murata","year":"2023","journal-title":"Am J Transplant"},{"key":"2026042720031301000_szag020-B5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s41232-020-00125-8","article-title":"Immune reaction and regulation in transplantation based on pluripotent stem cell technology","volume":"40","author":"Otsuka","year":"2020","journal-title":"Inflamm Regen"},{"key":"2026042720031301000_szag020-B6","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12943-023-01873-0","article-title":"Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy","volume":"22","author":"Chehelgerdi","year":"2023","journal-title":"Mol Cancer"},{"key":"2026042720031301000_szag020-B7","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.tibtech.2023.02.003","article-title":"Induced pluripotent stem cell-derived engineered T cells, natural killer cells, macrophages, and dendritic cells in immunotherapy","volume":"41","author":"Xue","year":"2023","journal-title":"Trends Biotechnol"},{"key":"2026042720031301000_szag020-B8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12958-015-0005-4","article-title":"Human embryonic stem cell cultivation: historical perspective and evolution of xeno-free culture systems","volume":"13","author":"Desai","year":"2015","journal-title":"Reprod Biol Endocrinol"},{"key":"2026042720031301000_szag020-B9","doi-asserted-by":"publisher","first-page":"62","DOI":"10.21037\/atm-22-6383","article-title":"Human serum albumin promotes self-renewal and expansion of umbilical cord blood CD34(+) hematopoietic stem\/progenitor cells","volume":"11","author":"Hua","year":"2023","journal-title":"Ann Transl Med"},{"key":"2026042720031301000_szag020-B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10616-010-9263-3","article-title":"Albumin and mammalian cell culture: implications for biotechnology applications","volume":"62","author":"Francis","year":"2010","journal-title":"Cytotechnology"},{"key":"2026042720031301000_szag020-B11","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1097\/01.ccm.0000169876.14858.91","article-title":"Heterogeneity and oxidation status of commercial human albumin preparations in clinical use","volume":"33","author":"Bar-Or","year":"2005","journal-title":"Crit Care Med"},{"key":"2026042720031301000_szag020-B12","doi-asserted-by":"publisher","first-page":"11508","DOI":"10.1021\/ac503864m","article-title":"Detection of contaminating enzymatic activity in plant-derived recombinant biotechnology products","volume":"86","author":"Brinson","year":"2014","journal-title":"Anal Chem"},{"key":"2026042720031301000_szag020-B13","doi-asserted-by":"publisher","first-page":"e109893","DOI":"10.1371\/journal.pone.0109893","article-title":"Determination of supplier-\u00adto-supplier and lot-to-lot variability in glycation of recombinant human serum albumin expressed in Oryza sativa","volume":"9","author":"Frahm","year":"2014","journal-title":"PLoS One"},{"key":"2026042720031301000_szag020-B14","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.stemcr.2017.01.015","article-title":"An all-recombinant protein-based culture system specifically identifies hematopoietic stem cell maintenance factors","volume":"8","author":"Ieyasu","year":"2017","journal-title":"Stem Cell Reports"},{"key":"2026042720031301000_szag020-B15","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/cr.2011.12","article-title":"Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures","volume":"21","author":"Chou","year":"2011","journal-title":"Cell Res"},{"key":"2026042720031301000_szag020-B16","doi-asserted-by":"publisher","first-page":"103113","DOI":"10.1016\/j.scr.2023.103113","article-title":"Generation of induced pluripotent stem cell lines from helper and cytotoxic T cells of healthy individuals","volume":"69","author":"Kamaldinov","year":"2023","journal-title":"Stem Cell Res"},{"key":"2026042720031301000_szag020-B17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/stem.1545","article-title":"Differential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient-specific induced pluripotent stem cells","volume":"32","author":"Ye","year":"2014","journal-title":"Stem Cells"},{"key":"2026042720031301000_szag020-B18","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1038\/nprot.2012.130","article-title":"Passaging and colony expansion of human pluripotent stem cells by enzyme-free dissociation in chemically defined culture conditions","volume":"7","author":"Beers","year":"2012","journal-title":"Nat\u00a0Protoc"},{"key":"2026042720031301000_szag020-B19","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/nprot.2008.42","article-title":"A protocol describing the use of a recombinant protein-based, animal product-free medium (APEL) for human embryonic stem cell differentiation as spin embryoid bodies","volume":"3","author":"Ng","year":"2008","journal-title":"Nat Protoc"},{"key":"2026042720031301000_szag020-B20","doi-asserted-by":"publisher","first-page":"320","DOI":"10.5966\/sctm.2014-0214","article-title":"A facile method to establish human induced pluripotent stem cells from adult blood cells under feeder-free and xeno-free culture conditions: a clinically compliant approach","volume":"4","author":"Chou","year":"2015","journal-title":"Stem Cells Transl Med"},{"key":"2026042720031301000_szag020-B21","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/trf.17239","article-title":"A report on a modified protocol for flow cytometry-based assessment of blood group erythrocyte antigens potentially suitable for analysis of weak ABO subgroups","volume":"63","author":"Otsu","year":"2023","journal-title":"Transfusion"},{"key":"2026042720031301000_szag020-B22","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3343\/alm.2014.34.4.300","article-title":"Comparison of ABO antibody titers on the basis of the antibody detection method used","volume":"34","author":"Kang","year":"2014","journal-title":"Ann Lab Med"},{"key":"2026042720031301000_szag020-B23","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/stem.1969","article-title":"Production of gene-corrected adult beta globin protein in human erythrocytes differentiated from patient iPSCs after genome editing of the sickle point mutation","volume":"33","author":"Huang","year":"2015","journal-title":"Stem Cells"},{"key":"2026042720031301000_szag020-B24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/978-1-4939-9728-2_12","article-title":"An improved method to produce clinical-scale natural killer cells from human pluripotent stem cells","volume":"2048","author":"Zhu","year":"2019","journal-title":"Methods Mol Biol"},{"key":"2026042720031301000_szag020-B25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/CJI.0000000000000402","article-title":"TCR-independent activation in presence of a Src-family kinase inhibitor improves CAR-T cell product attributes","volume":"45","author":"Lamture","year":"2022","journal-title":"J Immunother"},{"key":"2026042720031301000_szag020-B26","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1182\/blood-2005-03-0987","article-title":"Forced aggregation of defined numbers of human embryonic stem cells into embryoid bodies fosters robust, reproducible hematopoietic differentiation","volume":"106","author":"Ng","year":"2005","journal-title":"Blood"},{"key":"2026042720031301000_szag020-B27","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1126\/science.1191536","article-title":"Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells","volume":"329","author":"Boitano","year":"2010","journal-title":"Science"},{"key":"2026042720031301000_szag020-B28","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1126\/science.1256337","article-title":"Cord blood expansion. Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal","volume":"345","author":"Fares","year":"2014","journal-title":"Science"},{"key":"2026042720031301000_szag020-B29","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41586-019-1244-x","article-title":"Long-term ex vivo haematopoietic-stem-cell expansion allows nonconditioned transplantation","volume":"571","author":"Wilkinson","year":"2019","journal-title":"Nature"},{"key":"2026042720031301000_szag020-B30","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.exphem.2011.12.005","article-title":"Nicotinamide, a SIRT1 inhibitor, inhibits differentiation and facilitates expansion of hematopoietic progenitor cells with enhanced bone marrow homing and engraftment","volume":"40","author":"Peled","year":"2012","journal-title":"Exp Hematol"},{"key":"2026042720031301000_szag020-B31","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.stem.2019.02.012","article-title":"The NAD-Booster nicotinamide riboside potently stimulates hematopoiesis through increased mitochondrial clearance","volume":"24","author":"Vannini","year":"2019","journal-title":"Cell Stem Cell"},{"key":"2026042720031301000_szag020-B32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.exphem.2019.11.007","article-title":"Use of polyvinyl alcohol for chimeric antigen receptor T-cell expansion","volume":"80","author":"Nishimura","year":"2019","journal-title":"Exp Hematol"},{"key":"2026042720031301000_szag020-B33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41586-023-05739-9","article-title":"Chemically defined cytokine-free expansion of human haematopoietic stem cells","volume":"615","author":"Sakurai","year":"2023","journal-title":"Nature"},{"key":"2026042720031301000_szag020-B34","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ejps.2011.11.025","article-title":"Soluplus(R) as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo","volume":"45","author":"Linn","year":"2012","journal-title":"Eur J Pharm Sci"},{"key":"2026042720031301000_szag020-B35","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.biopha.2014.12.028","article-title":"Soluplus((R)) micelles as a potential drug delivery system for reversal of resistant tumor","volume":"69","author":"Jin","year":"2015","journal-title":"Biomed Pharmacother"},{"key":"2026042720031301000_szag020-B36","doi-asserted-by":"publisher","DOI":"10.3390\/cells9102270","article-title":"Cell mechanics in embryoid bodies","volume":"9","author":"Zeevaert","year":"2020","journal-title":"Cells"},{"key":"2026042720031301000_szag020-B37","doi-asserted-by":"publisher","first-page":"eabn6373","DOI":"10.1126\/sciimmunol.abn6373","article-title":"Cis interactions between CD2 and its ligands on T cells are required for T cell activation","volume":"7","author":"Li","year":"2022","journal-title":"Sci Immunol"},{"key":"2026042720031301000_szag020-B38","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1182\/blood-2010-06-291898","article-title":"Critical role of transcription factor PU.1 in the expression of CD80 and CD86 on dendritic cells","volume":"117","author":"Kanada","year":"2011","journal-title":"Blood"},{"key":"2026042720031301000_szag020-B39","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3727\/096368911X605367","article-title":"Matrix metalloproteinase-9 contributes to the mobilization of bone marrow cells in the injured liver","volume":"21","author":"Kawai","year":"2012","journal-title":"Cell Transplant"},{"key":"2026042720031301000_szag020-B40","doi-asserted-by":"publisher","first-page":"6462","DOI":"10.1073\/pnas.94.12.6462","article-title":"CCAAT\/enhancer binding protein epsilon is preferentially up-regulated during granulocytic differentiation and its functional versatility is determined by alternative use of promoters and differential splicing","volume":"94","author":"Yamanaka","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026042720031301000_szag020-B41","doi-asserted-by":"publisher","first-page":"5473","DOI":"10.1182\/blood-2009-04-217406","article-title":"Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders","volume":"114","author":"Ye","year":"2009","journal-title":"Blood"},{"key":"2026042720031301000_szag020-B42","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"2026042720031301000_szag020-B43","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"2026042720031301000_szag020-B44","doi-asserted-by":"publisher","first-page":"6224","DOI":"10.1073\/pnas.0601462103","article-title":"The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation","volume":"103","author":"Jamieson","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026042720031301000_szag020-B45","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1182\/blood-2006-10-054940","article-title":"The JAK2 617V&gt;F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera","volume":"110","author":"Dupont","year":"2007","journal-title":"Blood"},{"key":"2026042720031301000_szag020-B46","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1182\/blood-2009-04-215848","article-title":"Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease","volume":"115","author":"Akada","year":"2010","journal-title":"Blood"},{"key":"2026042720031301000_szag020-B47","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1172\/JCI109003","article-title":"Polycythemia vera. The in vitro response of normal and abnormal stem cell lines to erythropoietin","volume":"61","author":"Prchal","year":"1978","journal-title":"J Clin Invest"},{"key":"2026042720031301000_szag020-B48","doi-asserted-by":"publisher","first-page":"6094","DOI":"10.1182\/blood-2008-06-165225","article-title":"Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity","volume":"113","author":"Woll","year":"2009","journal-title":"Blood"},{"key":"2026042720031301000_szag020-B49","doi-asserted-by":"publisher","DOI":"10.3390\/ph12010015","article-title":"Micellisation mechanism and behaviour of soluplus(R)(-)furosemide micelles: preformulation studies of an oral nanocarrier-based system","volume":"12","author":"Alopaeus","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026042720031301000_szag020-B50","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1095\/biolreprod.104.036673","article-title":"Growth and differentiation of embryoid bodies derived from human embryonic stem cells: effect of glucose and basic fibroblast growth factor","volume":"73","author":"Khoo","year":"2005","journal-title":"Biol Reprod"},{"key":"2026042720031301000_szag020-B51","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4252\/wjsc.v1.i1.11","article-title":"Embryoid body formation from embryonic and induced pluripotent stem cells: benefits of bioreactors","volume":"1","author":"Rungarunlert","year":"2009","journal-title":"World J Stem Cells"},{"key":"2026042720031301000_szag020-B52","doi-asserted-by":"publisher","first-page":"7402","DOI":"10.1038\/srep07402","article-title":"Formation of well-defined embryoid bodies from dissociated human induced pluripotent stem cells using microfabricated cell-repellent microwell arrays","volume":"4","author":"Pettinato","year":"2014","journal-title":"Sci Rep"},{"key":"2026042720031301000_szag020-B53","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/s41587-024-02360-7","article-title":"Long-term engrafting multilineage hematopoietic cells differentiated from human induced pluripotent stem cells","volume":"43","author":"Ng","year":"2025","journal-title":"Nat Biotechnol"}],"container-title":["Stem Cells Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/15\/5\/szag020\/68171845\/szag020.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/15\/5\/szag020\/68171845\/szag020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:03:18Z","timestamp":1777334598000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stcltm\/article\/doi\/10.1093\/stcltm\/szag020\/8663657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4,27]]}},"URL":"https:\/\/doi.org\/10.1093\/stcltm\/szag020","relation":{},"ISSN":["2157-6564","2157-6580"],"issn-type":[{"value":"2157-6564","type":"print"},{"value":"2157-6580","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,4,27]]},"article-number":"szag020"}}